BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Johnson & Johnson’s third quarter told two stories. Operationally, it was a beat and raise: adjusted EPS of $2.59 topped the $2.53 consensus, sales grew 5.9% to $25.4 billion, and management lifted full-year guidance toward the first $100-billion-plus revenue year in company history. On a GAAP basis, reported EPS collapsed to $0.09 as a one-time talc-litigation charge wiped out nearly all of the quarter’s profit.
Key figures (Q3 2026):
- Adjusted EPS: $2.59 vs $2.53 consensus (-7.5% YoY on deal costs)
- Sales: $25.399 billion (+5.9% YoY), operational growth 6.0%
- FY2026 guidance raised: sales $101.0–$101.4B, adjusted EPS $11.05–$11.15
- Innovative Medicine: +7.9% operationally to $16.8B; MedTech: +2.5% to $8.6B (a miss)
- GAAP EPS: $0.09 (vs $2.12) on talc, Firefly Bio and Sail Biomedicines charges
The pharmaceutical engine keeps firing. Innovative Medicine grew 7.9% operationally to $16.8 billion, led by Tremfya, Darzalex and Carvykti — offsetting biosimilar pressure on Stelara. MedTech, however, underwhelmed for a second straight quarter, with weakness in cardiovascular and surgery outside the U.S.; the CFO signaled a preference for spinning out the orthopedics (hips-and-knees) business rather than selling it.
The raised guidance was modest — sales midpoint to $101.2 billion (+7.4%) and adjusted EPS midpoint to $11.10 (+2.9%, up six cents) — and the stock traded under pressure as investors judged the raise shy of elevated expectations, with new drug deals expected to weigh on 2027 earnings. For income investors, the $1.34 quarterly dividend remains the anchor while the litigation overhang lingers.
Related reading: Morning Briefing Oct 13: Chip Rout Deepens, Bank Earnings, CPI Ahead, How Midterm Octobers Have Treated Stocks
What to watch: J&J keeps raising the guide while MedTech keeps lagging — and an orthopedics spinoff is now on the table. Would spinning out hips-and-knees unlock value, or is it just window dressing? Share your view below.
Sources:
https://www.biospace.com/press-releases/johnson-johnson-reports-q3-2026-results-raises-2026-guidance
Auto-posted by the Bull Lounge news desk.
Not financial advice.
Log in to vote
